Browse by popular tags
abvd ac220 act acute lymphoblastic leukaemia acute myelogenous leukemia (aml) acute myeloid leukaemia ade admire adoptive cellular therapy alemtuzumab all allogeneic allogeneic stem cell transplant amgen aml aml 17 aml 18 pilot angioimmunoblastic lymphoma antiviral therapy arctic aspirin autologous stem cell transplant autologous transplant azacitidine b-cell b-cell chronic lymphocytic leukaemia blood cancers bone marrow bortezomib
NHS Logo
The Clinical research facility is part of the NIHR and is funded by the Department of Health
Phase II strudy of Bortezomib, Adriamycin and Dexamethasone (PAD) therapy for previously untreated patients with multiple myeloma: Impact of minimal residual disease (MRD) in patients with deferred ASCT.
The overall aim of the trial is to provide a reliable estimate of the 2-year PFS for patients who receive no further treatment after achieving a major response to induction therapy with PAD.